Upregulation of SPAG6 is a frequent event in AML patients and indicates a poor prognosis in human AML. (A) The public data on AML were obtained from GEO (Gene Expression Omnibus) databases, and the mRNA expression levels of SPAG6 in AML and control samples were statistically analyzed. (B) The mRNA level of SPAG6 in 3 independent datasets GSE9476, GSE138702, and GSE13159. (C) SPAG6 expression in tumor and normal tissues was analyzed on the website https://www.oncomine.org/. (D) Real-time polymerase chain reaction analysis of SPAG6 mRNA expression in AML patients (n = 28) and control samples (n = 10). (E) SPAG6 expression in CD34⁺ leukemia stem cells from AML patients (n = 7) and control samples (n = 6). (F) Western blot analysis of SPAG6 protein expression in AML patients (n = 18) and control samples (n = 8). (G) The mRNA and protein level of SPAG6 in normal hematopoietic cells and K562, THP-1, HL-60, and HEL cells. (H) Overall survival analyses between patients with high or low SPAG6 expression in TCGA and GSE37642 dataset. (I) SPAG6 expression from AML patients (n = 35) with various cytogenetic aberrations. (J) The correlation between SPAG6 expression and AML CALGB cytogenetics risk category in TCGA database. (K) SPAG6 expression from AML patients with various cytogenetic aberrations (GSE13159). (L) SPAG6 expression from AML patients with different risk status in Vizome-ELN2017. *P < .05; **P < .01. LCSs, leukemia stem cells.